stockrowEdwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.
- Revenue
- +10.5%
- EPS
- +6.00%
- Free cash flow
- −1.84%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow EW
Alert me
Edwards Lifesciences Corporation (EW) Return on equity
Edwards Lifesciences Corporation's return on equity over the twelve months to 30 September 2026 was 9.65%, down 0.9 percentage points from fiscal 2025 (10.5%). Over the past ten years it has ranged from 10.5% (fiscal 2025) to 49.8% (fiscal 2024) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.5% | (39.23) |
| FY2024 | 49.8% | 27.36 |
| FY2023 | 22.4% | (3.75) |
| FY2022 | 26.1% | (2.74) |
| FY2021 | 28.9% | 10.00 |
| FY2020 | 18.9% | (9.85) |
| FY2019 | 28.7% | 5.04 |
| FY2018 | 23.7% | 2.75 |
| FY2017 | 20.9% | (1.30) |
| FY2016 | 22.2% | 1.16 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. compare | 37.7% |
| GEHC GE HealthCare Technologies Inc. compare | 19.9% |
| SYK Stryker Corporation compare | 16.0% |
| BSX Boston Scientific Corporation compare | 14.2% |
| STE STERIS plc compare | 11.6% |
| MDT Medtronic PLC compare | 10.6% |
| EW Edwards Lifesciences Corporation | 9.65% |
| PHG Koninklijke Philips N.V. compare | 8.54% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6.02% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on EW
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement